Daily Cardiology Research Analysis
Across cardiology this cycle, an individual participant–level meta-analysis shows empagliflozin durably reduces acute and chronic kidney adverse outcomes irrespective of the initial eGFR dip or comorbidity profile. A population-based cohort reveals that co-occurring covert brain infarction and unrecognized myocardial infarction marks a subgroup with markedly elevated ASCVD risk. In the cath lab, a prospective study validates real-time vessel FFR as an accurate and faster alternative to wire-base
Summary
Across cardiology this cycle, an individual participant–level meta-analysis shows empagliflozin durably reduces acute and chronic kidney adverse outcomes irrespective of the initial eGFR dip or comorbidity profile. A population-based cohort reveals that co-occurring covert brain infarction and unrecognized myocardial infarction marks a subgroup with markedly elevated ASCVD risk. In the cath lab, a prospective study validates real-time vessel FFR as an accurate and faster alternative to wire-based FFR.
Research Themes
- SGLT2 inhibition confers kidney protection across diverse cardiometabolic populations
- Silent ischemia in brain and heart synergistically elevates future ASCVD risk
- Angiography-based functional physiology (vFFR) accelerates decision-making with high diagnostic accuracy
Selected Articles
1. Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.
Across four large randomized trials (n=23,340), empagliflozin reduced acute kidney injury (AKI) markers by 20% and AKI adverse events by 27%, lowered chronic kidney disease progression by 30% and kidney failure by 34%, and slowed chronic eGFR decline by 64%. Benefits were consistent irrespective of the size of the acute eGFR dip, diabetes or heart failure status, primary kidney disease, or albuminuria.
Impact: This IPD meta-analysis resolves a key safety concern by showing kidney benefits independent of the acute eGFR dip and across disease contexts, strengthening the case for broad SGLT2i use in cardiometabolic care.
Clinical Implications: Supports initiating empagliflozin in CKD and cardiometabolic populations without withholding due to expected acute eGFR dips, to prevent AKI, CKD progression, and kidney failure while slowing eGFR decline.
Key Findings
- Reduced AKI marker events by 20% and AKI adverse events by 27% versus placebo.
- Lowered CKD progression by 30% and kidney failure by 34%.
- Slowed chronic annual eGFR decline by 64%, consistent regardless of acute eGFR dip size.
- Benefits were consistent across diabetes status, heart failure status, primary kidney disease, and albuminuria.
Methodological Strengths
- Individual participant-level meta-analysis across four randomized controlled trials
- Robust subgroup analyses including predicted acute eGFR dip and key comorbidities
Limitations
- Heterogeneity in outcome definitions and follow-up across trials
- Trial populations may limit generalizability to unrepresented subgroups
Future Directions: Outcomes-based implementation studies to optimize SGLT2i initiation timing and integration with RAAS blockade/ARNI across CKD phenotypes, and mechanistic work on dip-independent renoprotection.
BACKGROUND: Uncertainty remains about effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on kidney outcomes in individuals with slowly progressive chronic kidney disease (eg, low albuminuria) and those at risk of large acute estimated glomerular filtration rate (eGFR) dips on initiation of such treatment. We aimed to explore the effects of empagliflozin on a range of kidney outcomes in these population subtypes. METHODS: In this meta-analysis, we used individual-level data from 23 340 participants in four large place
2. Risk of Cardiovascular Disease With Co-Occurring Covert Brain Infarction and Unrecognized Myocardial Infarction.
In 4,627 adults from the Rotterdam Study (mean follow-up 9.9 years), CBI and UMI were interrelated and each associated with higher ASCVD risk. Co-occurrence of CBI and UMI conferred the highest risk (HR 5.6; 95% CI 2.9–10.7) versus neither lesion. Among individuals with CBI, concomitant UMI tripled ASCVD risk compared with CBI alone.
Impact: Defines a readily identifiable, very high-risk subgroup using ECG and brain MRI findings, enabling intensified preventive therapy targeting ASCVD.
Clinical Implications: Patients with both CBI and UMI warrant aggressive risk factor control (statins, BP control), antithrombotic optimization, and close surveillance given markedly elevated ASCVD risk.
Key Findings
- CBI and UMI co-occurred more frequently than expected; CBI doubled the odds of UMI (OR 2.3).
- Co-occurring CBI+UMI yielded HR 5.6 (95% CI 2.9–10.7) for incident ASCVD versus neither lesion.
- Among 359 individuals with CBI, concomitant UMI increased ASCVD risk (HR 3.4; 95% CI 1.7–6.7) versus CBI alone.
Methodological Strengths
- Population-based prospective cohort with nearly 10-year mean follow-up
- Multivariable Cox models adjusting for cardiovascular risk factors
Limitations
- UMI detection relied on ECG, potentially underdetecting silent infarcts
- Observational design cannot eliminate residual confounding
Future Directions: Test whether intensified preventive regimens guided by combined CBI+UMI status reduce ASCVD events; refine imaging/ECG algorithms for silent ischemia detection.
BACKGROUND: Covert brain infarction (CBI) increases the risk of atherosclerotic cardiovascular disease (ASCVD), but optimal clinical management is uncertain. To enable tailored preventive measures, we aimed to determine whether the co-occurrence of CBI with unrecognized myocardial infarction (UMI) identifies a subgroup at especially high risk of ASCVD. METHODS: We included participants from the population-based Rotterdam Study, who were aged ≥45 years and without a history of stroke, transient ischemic attack or myo
3. VERMONT: Vessel Fractional Flow Reserve (vFFR) Assessment of Stenosis Severity: A Prospective Study.
In 209 patients with 225 intermediate lesions, real-time vFFR showed excellent diagnostic performance versus wire-based FFR (AUC 0.92; 90% sensitivity; 79% specificity; NPV 93%) with a low exclusion rate (8.9%). Computation was on average 13.9 minutes faster than wire-based FFR, with excellent interobserver agreement (r=0.97).
Impact: Demonstrates that angiography-based vFFR can accurately screen functionally significant lesions while saving procedural time, supporting scalable physiology-first strategies.
Clinical Implications: vFFR can triage intermediate lesions quickly with high NPV, potentially reducing wire-based FFR use, contrast, and procedure time while maintaining physiologic decision quality.
Key Findings
- AUC 0.92 with 90% sensitivity, 79% specificity, and 93% NPV versus FFR≤0.80 reference.
- Real-time vFFR was on average 13.9 minutes faster than wire-based FFR.
- Low exclusion rate (8.9%) and excellent interobserver agreement (r=0.97).
Methodological Strengths
- Prospective, blinded head-to-head comparison against wire-based FFR
- Comprehensive reporting of diagnostic metrics and workflow time
Limitations
- Single-center design may limit generalizability
- Lacked clinical outcomes to confirm management impact
Future Directions: Multicenter outcome-driven trials to test vFFR-guided strategy versus standard care, and cost-effectiveness analyses in diverse cath lab settings.
BACKGROUND: Vessel fractional flow reserve (vFFR) is an angiogram-based technique validated in early studies; however, data on its real-time diagnostic performance and integration into routine workflow remain limited. AIMS: The VERMONT study evaluated the diagnostic accuracy and time efficiency of real-time vFFR versus conventional wire-based FFR in detecting functionally significant coronary lesions. METHODS: We conducted a prospective, single-center, blinded study in which vFFR was measured during coronary an